

FOR HEALTH CARE PROVIDERS

DEDICATED ACCESS SUPPORT WHEN PRESCRIBING CTEXLI[®] (chenodiol) tablets

Mirum Access Plus Is With You
Every Step of the Way

Mirum Access Plus works alongside you and your patients at every turn—offering dedicated support when and where it's needed.



Mirum Access Plus will support you through the payer approval process and will help determine financial support options for eligible patients



Mirum Access Plus helps your patients understand the process to access their prescribed medication and keeps them informed along the way



Mirum Access Plus also offers enrolled patients educational materials, referrals to outside resources, and ongoing support

INDICATION

CTEXLI is indicated for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hepatotoxicity: Chenodiol, including CTEXLI, has been associated with hepatotoxicity. Patients with preexisting liver disease or bile duct abnormalities may be at a higher risk for hepatotoxicity during treatment.

Please see Important Safety Information throughout and accompanying full Prescribing Information.

IF YOU HAVE ANY QUESTIONS ABOUT MIRUM ACCESS PLUS,
CONTACT US AT:



1-855-MRM-4YOU (1-855-676-4968)

Monday to Friday, 8 AM to 8 PM ET



Understanding the Steps

HELP YOUR PATIENTS SECURE ACCESS TO CTEXLI[®] (chenodiol) tablets

After prescribing CTEXLI, you play an important role in helping your patients access their medicine without delay.

STEP 1



Complete the Patient Enrollment Form

- **Include insurance information** by providing a copy of the patient's insurance card (front and back) and/or a copy of the patient's demographics from electronic medical records. Ensure that the prescription drug benefit information or card is included
- **Complete all required fields** (marked with an asterisk) to avoid processing delays
- **Encourage patients/caregivers to consent** to receive Mirum Access Plus services and text messages to get the most support from the program

STEP 2



Determine Insurance Coverage

- **A dedicated Mirum Access Plus Coordinator will perform a benefits verification**, which will determine:
 - Coverage of CTEXLI and whether an authorization is necessary for the patient's health plan
 - Patient need and eligibility for financial support options that may help with out-of-pocket costs, such as a \$0 savings program* or the potential to receive the drug free of charge[†]

STEP 3



Complete Payer Approval Process

- **The correct prior authorization (PA) or medical exception (ME) form will be provided to your office from Mirum Access Plus or directly from the payer.** Mirum Access Plus will follow up with the payer until a determination is made
- Once approved, the **coverage authorization status will be communicated** to your office and the patient or caregiver

*Pay as little as \$0 per fill for commercially insured patients. Subject to program terms and conditions.

[†]Drug free of charge through the Mirum Patient Assistance Program (PAP) if your patient is uninsured or their health plan does not offer coverage. Subject to program terms and conditions.

Please see Important Safety Information throughout and accompanying full [Prescribing Information](#).

PRESCRIBING OPTIONS:



Fax the CTEXLI Enrollment Form to 1-855-282-4884



E-prescribe CTEXLI to EVERANA Life Science Services

STEP 4

STEP 5

**Appeal a Denial,
if Necessary**



- In the event of a denial, **Mirum Access Plus will share potential options for the appeal process**, including initiating a peer-to-peer discussion with the payer or assistance with submitting a formal appeal
- If the appeal is denied, **Mirum Access Plus will refer your patient to the Patient Assistance Program (PAP), as appropriate**. Completion of the health care professional portion of the PAP application will be necessary for evaluating your patient's eligibility for the PAP

**SP Dispenses
CTEXLI[®] (chenodiol)**



- **Mirum Access Plus** specialty pharmacy (SP) will provide a therapy consultation call covering instructions for use before coordinating the overnight shipment of CTEXLI to the patient's home
- Mirum Access Plus SP provides 24/7 pharmacist availability for your patients
- Mirum Access Plus will perform active refill management to prevent gaps in therapy and will work with your office to resolve insurance requirements, such as reauthorizations

**Supporting Success
With CTEXLI Therapy**

Mirum Access Plus offers an enhanced, personalized experience for enrolled patients as they start and stay on therapy. A dedicated team of Mirum Access Plus Navigators will deliver simple and flexible patient support for medication and related wellness.

Please see Important Safety Information throughout and accompanying full [Prescribing Information](#).

IF YOU HAVE ANY QUESTIONS ABOUT MIRUM ACCESS PLUS,
CONTACT US AT:



1-855-MRM-4YOU (1-855-676-4968)

Monday to Friday, 8 AM to 8 PM ET



PRESCRIBING OPTIONS:



Fax the CTEXLI Enrollment Form to 1-855-282-4884



E-prescribe CTEXLI to EVERSANA Life Science Services

IMPORTANT SAFETY INFORMATION (con't)

Hepatotoxicity: Before initiating CTEXLI, obtain baseline liver transaminase (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) and total bilirubin levels in all patients. Monitor liver transaminase (ALT, AST) and total bilirubin levels yearly and as clinically indicated. If liver transaminase levels are elevated >3 times the upper limit of normal (ULN) or total bilirubin level is >2 times ULN, interrupt treatment until the levels have returned to baseline values. For persistent or recurrent liver test abnormalities, consider discontinuing CTEXLI. Inform the patient of the symptoms of hepatotoxicity (e.g., abdominal pain, bruising, dark-colored urine, fatigue, bleeding, jaundice, nausea, and pruritus). Have the patient discontinue CTEXLI immediately if clinical signs and symptoms consistent with hepatotoxicity occur.

ADVERSE REACTIONS

The most common adverse reactions ($\geq 14\%$) during CTEXLI treatment were diarrhea, headache, abdominal pain, constipation, hypertension, muscular weakness, and upper respiratory tract infection.

DRUG INTERACTIONS

Bile acid sequestering agents and aluminum-based antacids: Avoid concomitant use with CTEXLI. Co-administration of bile acid sequestering agents, such as cholestyramine and colestipol, or aluminum-based antacids may decrease absorption of CTEXLI in the intestine and may result in decreased efficacy.

Coumarin and its derivatives: Monitor prothrombin time and adjust the dosage of coumarin or its derivatives if concomitant use with CTEXLI is unavoidable. Due to potential hepatotoxicity, CTEXLI may affect the pharmacodynamics of coumarin and its derivatives, causing unexpected prolongation of the prothrombin time and hemorrhage.

DOSING AND ADMINISTRATION

The recommended dosage of CTEXLI is 250 mg administered orally three times daily, with or without food. Swallow tablets whole.

Please see Important Safety Information throughout and accompanying full Prescribing Information.

Additional resources can be found at CTEXLIhcp.com.

